HELSINKI, May 18 (Reuters) - Drugs group Orion Corp. (ORNBS.HE: Quote, Profile, Research) and licensing partner Abbott Laboratories (ABT.N: Quote, Profile, Research) are considering an additional Phase III clinical study on heart failure drug Simdax, Orion said on Thursday.
